NYMX Pengajuan SEC - Nymox Pharmaceutical Corp- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

CIK

1018735

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Nymox Pharmaceutical Corp

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

June 3, 2025	EX-12.(B)	CERTIFICATION EXHIBIT 12 (b) CERTIFICATION I, Patrick A. Doody, Vice President and General Counsel of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this annual report for the period ended December 31, 2024 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
June 3, 2025	20-F	United States Securities and Exchange Commission Washington, D.C. 20549 Form 20-F ☐ Registration Statement pursuant to section 12(b) or (g) of the Securities Exchange Act of 1934 ☒ Annual Report pursuant to section 13 or 15(d) of the Securities Excha United States Securities and Exchange Commission Washington, D.C. 20549 Form 20-F ☐ Registration Statement pursuant to section 12(b) or (g) of the Securities Exchange Act of 1934 or ☒ Annual Report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2024 or ☐ Transition Report pursuant to section 13 or 15(d) of the Securities Exchange Act o
June 3, 2025	EX-13.(A)	CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 13 (a) CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, do hereby certify that, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the information contained in the Annual Report for the period e
June 3, 2025	EX-12.(A)	CERTIFICATION EXHIBIT 12 (a) CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1.
June 3, 2025	EX-13.(B)	CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 13 (b) CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Patrick A. Doody, VP and General Counsel of Nymox Pharmaceutical Corporation, do hereby certify that, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the information contained in the Annual Report for the
May 22, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May, 2025 Commission File Number: 001-12033 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May, 2025 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation (Translation of registrant’s name into English) Bay & Deveaux Streets, Nassau, The Bahamas (Address of principal execut
May 1, 2025	NT 20-F	UNITED STATES UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0058 Expires: April 30, 2025 Estimated average burden hours per response...… … .2.50 FORM 12b-25 SEC FILE NUMBER CUSIP NUMBER NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☒ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2024 ☐ Transit
March 11, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March, 2025 Commission File Number: 001-12033 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March, 2025 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation (Translation of registrant’s name into English) Bay & Deveaux Streets, Nassau, The Bahamas (Address of principal exec
March 11, 2025	EX-99.1	Nymox Pharmaceutical Corporation EXHIBIT 99.1 For Further Information Contact: Nymox Pharmaceutical Corporation 1-800-93NYMOX www.nymox.com For Immediate Release: Nymox Announces Dismissal of Delaware Action Against Ascella IRVINE CA, March 11, 2025 (Globe Newswire). Nymox announces that it dismissed the Delaware matter pending against Ascella on March 7, 2025. A number of factors caused the company to reconsider its strategy to
January 2, 2025	EX-99.1	Less than 1 year EXHIBIT 99.1 MANAGEMENT’S DISCUSSION AND ANALYSIS (in US dollars) This is Management’s discussion and analysis (“MD&A”) comments on the Corporation’s operations, performance and financial condition as of and for the three and nine months ended September 30, 2024 and 2023. This MD&A should be read together with the unaudited interim Consolidated Financial Statements and the related notes. This MD&A
January 2, 2025	6-K	FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended September 30, 2024 Commission File Number: 001-12033 FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended September 30, 2024 Commission File Number: 001-12033 NYMOX PHARMACEUTICAL CORPORATION Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 2
January 2, 2025	EX-99.2	CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 99.2 CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended September 30, 2024 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, i
December 17, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December, 2024 Commission File Number: 001-120 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December, 2024 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation (Translation of registrant’s name into English) Bay & Deveaux Streets, Nassau, The Bahamas (Address of principal e
December 17, 2024	EX-99.1	Nymox Pharmaceutical Corporation EX-99.1 2 nymoxex991.htm PRESS RELEASE EXHIBIT 99.1 For Further Information Contact: Nymox Pharmaceutical Corporation 1-800-93NYMOX www.nymox.com For Immediate Release: NYMOX Announces Trading Resumed and New Listing on OTCQB Market IRVINE CA, December 17, 2024. Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets NYMXF) announced today that the Company's stock has resumed trading under the sym
August 29, 2024	EX-12.A	CERTIFICATION EXHIBIT 12 (a) CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1.
August 29, 2024	EX-12.B	CERTIFICATION EXHIBIT 12 (b) CERTIFICATION I, Patrick A. Doody, Vice President and General Counsel of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this annual report for the period ended December 31, 2023 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
August 29, 2024	EX-13.B	CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 13 (b) CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Patrick A. Doody, VP and General Counsel of Nymox Pharmaceutical Corporation, do hereby certify that, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the information contained in the Annual Report for the
August 29, 2024	20-F	United States Securities and Exchange Commission Washington, D.C. 20549 Form 20-F ☐ Registration Statement pursuant to section 12(b) or (g) of the Securities Exchange Act of 1934 ☒ Annual Report pursuant to section 13 or 15(d) of the Securities Excha United States Securities and Exchange Commission Washington, D.C. 20549 Form 20-F ☐ Registration Statement pursuant to section 12(b) or (g) of the Securities Exchange Act of 1934 or ☒ Annual Report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2023 or ☐ Transition Report pursuant to section 13 or 15(d) of the Securities Exchange Act o
August 29, 2024	EX-13.A	CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 13 (a) CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, do hereby certify that, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the information contained in the Annual Report for the period e
July 18, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July, 2024 Commission File Number: 001-12033 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July, 2024 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation (Translation of registrant’s name into English) Bay & Deveaux Streets, Nassau, The Bahamas (Address of principal execu
July 18, 2024	EX-99.1	Nymox Pharmaceutical Corporation EXHIBIT 99.1 For Further Information Contact: Nymox Pharmaceutical Corporation 1-800-93NYMOX www.nymox.com For Immediate Release: Nymox Annual Report IRVINE CA, July 18, 2024. Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets NYMXF) announced today that its Annual Report is and has been in progress since late February, soon after Nymox received some of its corporate documents withheld by the
July 16, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July, 2024 Commission File Number: 001-12033 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July, 2024 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation (Translation of registrant’s name into English) Bay & Deveaux Streets, Nassau, The Bahamas (Address of principal execu
July 16, 2024	EX-99.1	2 EXHIBIT 99.1 For Further Information Contact: Nymox Pharmaceutical Corporation1-800-93NYMOX www.nymox.com For Immediate Release: Nymox Required to Resubmit Application to DKMA IRVINE CA, July 16, 2024. Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets NYMXF) announced today that its MAA submission to the Danish Medicines Agency (DKMA) has run out of time and in order to continue will be requ
May 13, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May, 2024 Commission File Number: 001-12033 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May, 2024 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation (Translation of registrant’s name into English) Bay & Deveaux Streets, Nassau, The Bahamas (Address of principal execut
May 13, 2024	EX-99.1	May 13, 2024 EXHIBIT 99.1 May 13, 2024 Office of the Chief Accountant Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Re: Nymox Pharmaceutical Corporation Ladies and Gentlemen: We have read Nymox Pharmaceutical Corporation’s Form 6-K dated May 13, 2024, and we agree with the statements set forth in the Form 6-K, insofar as they relate to our firm. We have no basis to agree or disagr
March 28, 2024	EX-99.1	EX-99.1 EXHIBIT 99.1
March 28, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March, 2024 Commission File Number: 001-12033 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March, 2024 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation (Translation of registrant’s name into English) Bay & Deveaux Streets, Nassau, The Bahamas (Address of principal exec
November 15, 2023	EX-99.1	Less than 1 year EXHIBIT 99.1 MANAGEMENT’S DISCUSSION AND ANALYSIS (in US dollars) This is Management’s discussion and analysis (“MD&A”) comments on the Corporation’s operations, performance and financial condition as of and for the three and nine months ended September 30, 2023 and 2022. This MD&A should be read together with the unaudited interim Consolidated Financial Statements and the related notes. This MD&A
November 15, 2023	EX-99.2	CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 99.2 CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended September 30, 2023 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, i
November 15, 2023	6-K	FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended September 30, 2023 Commission File Number: 001-12033 FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended September 30, 2023 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 2
November 9, 2023	EX-99.1	Nymox Pharmaceutical Corporation EXHIBIT 99.1 NEWS RELEASE For Further Information Contact: Nymox Pharmaceutical Corporation 1-800-93NYMOX www.nymox.com For Immediate Release: Nymox Pharmaceutical Corporation Sues AscellaHealth For $250 Million IRVINE CA, November 9, 2023. This week, Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets - NYMXF) was forced to file a lawsuit in California Superior Court, Orange County, to protec
November 9, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November, 2023 Commission File Number: 001-120 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November, 2023 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation (Translation of registrant’s name into English) Bay & Deveaux Streets, Nassau, The Bahamas (Address of principal e
November 6, 2023	EX-99.1	Nymox Pharmaceutical Corporation EXHIBIT 99.1 For Further Information Contact: Nymox Pharmaceutical Corporation 1-800-93NYMOX www.nymox.com For Immediate Release: Notice: Nymox Informs Its Shareholders Not to Take Calls or Participate in An Unauthorized and Improper Shareholder Meeting IRVINE, CA (October 27, 2023) -The following is Nymox's response to an unauthorized shareholder meeting: Nymox Pharmaceutical Corporation [OTC Mar
November 6, 2023	EX-99.3	Nymox Pharmaceutical Corporation EXHIBIT 99.3 For Further Information Contact: Nymox Pharmaceutical Corporation 1-800-93NYMOX www.nymox.com For Immediate Release: IMPORTANT MESSAGE TO NYMOX SHAREHOLDERS: NYMOX Cautions Against Unauthorized Improper Shareholder Meeting and Unauthorized Unregistered Solicitations IRVINE CA, November 2, 2023. The following is Nymox's response to an unauthorized shareholder meeting: Nymox Pharmaceuti
November 6, 2023	EX-99.4	Nymox Pharmaceutical Corporation EXHIBIT 99.4 For Further Information Contact: Nymox Pharmaceutical Corporation 1-800-93NYMOX www.nymox.com For Immediate Release: NYMOX REPORTS NOTICE: California Court Issued A Temporary Restraining Order Enjoining Lanham, Riley, Cutler And Their Nevada Company After Court Hearing In Santa Ana, California, November 2, 2023 Ex-Employees and Agents, and those working in concert with them, are order
November 6, 2023	EX-99.2	IMPORTANT NOTICE: NYMOX Cautions Shareholders Not to Take Calls or Participate in Unauthorized Improper Shareholder Meeting EXHIBIT 99.2 For Further Information Contact: Nymox Pharmaceutical Corporation 1-800-93NYMOX www.nymox.com For Immediate Release: IMPORTANT NOTICE: NYMOX Cautions Shareholders Not to Take Calls or Participate in Unauthorized Improper Shareholder Meeting IRVINE CA, October 31, 2023. The following is Nymox's response to an unauthorized shareholder meeting: Nymox Pharmaceutical Corporation [OTC Marke
November 6, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Months of October and November, 2023 Commission File Nu UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Months of October and November, 2023 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation (Translation of registrant’s name into English) Bay & Deveaux Streets, Nassau, The Bahamas (Address o
November 6, 2023	EX-99.5	Nymox Pharmaceutical Corporation EXHIBIT 99.5 For Further Information Contact: Nymox Pharmaceutical Corporation 1-800-93NYMOX www.nymox.com For Immediate Release: NYMOX REPORTS: Bahamian Court Today Suspends Order of October 3, 2023 Rendering Riley-Lanham and Accomplices Planned Vote Unauthorized IRVINE CA, November 3, 2023. Nymox Pharmaceutical Corporation (“Nymox” or the "Company") [OTC Markets-NYMXF] is pleased to announce tha
October 26, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October, 2023 Commission File Number: 001-1203 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October, 2023 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation (Translation of registrant’s name into English) Bay & Deveaux Streets, Nassau, The Bahamas (Address of principal ex
October 26, 2023	EX-99.1	Nymox Pharmaceutical Corporation EXHIBIT 99.1 NEWS RELEASE For Further Information Contact: Nymox Pharmaceutical Corporation 1-800-93NYMOX www.nymox.com For Immediate Release: Nymox Reports New NYMOZARFEX Marketing Application is Accepted For Review IRVINE, CA (October 26, 2023) Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is pleased to announce that the Company's recent submission of Fexapotide Trifluta
September 25, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September, 2023 Commission File Number: 001-12 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September, 2023 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation (Translation of registrant’s name into English) Bay & Deveaux Streets, Nassau, The Bahamas (Address of principal
September 25, 2023	EX-99.1	NEWS RELEASE EXHIBIT 99.1 NEWS RELEASE For Further Information Contact: Nymox Pharmaceutical Corporation 1-800-93NYMOX www.nymox.com For Immediate Release: Nymox Announces Submission of New Marketing Authorization Application Submission for NYMOZARFEX (TM) for BPH IRVINE, CA (September 25, 2023) Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is pleased to announce today that a new forma
August 29, 2023	EX-99.1	NEWS RELEASE EXHIBIT 99.1 NEWS RELEASE For Further Information Contact: Nymox Pharmaceutical Corporation 1-800-93NYMOX www.nymox.com For Immediate Release: Nymox Reports Completion of $2 Million Private Placement IRVINE, CA (August 29, 2023) Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is pleased to announce the completion of its recently reported private placement of USD 2 million. T
August 29, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August, 2023 Commission File Number: 001-12033 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August, 2023 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation (Translation of registrant’s name into English) Bay & Deveaux Streets, Nassau, The Bahamas (Address of principal exe
August 14, 2023	EX-99.2	CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 99.2 CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended June 30, 2023 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in lig
August 14, 2023	EX-99.1	Less than 1 year EXHIBIT 99.1 MANAGEMENT'S DISCUSSION AND ANALYSIS (in US dollars) This is Management’s discussion and analysis (“MD&A”) comments on the Corporation’s operations, performance and financial condition as of and for the three and six months ended June 30, 2023 and 2022. This MD&A should be read together with the unaudited condensed interim Consolidated Financial Statements and the related notes. This
August 14, 2023	6-K	FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended June 30, 2023 Commission File Number: 001-12033 FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended June 30, 2023 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ☒
August 2, 2023	EX-99.1	NEWS RELEASE EXHIBIT 99.1 NEWS RELEASE For Further Information Contact: Nymox Pharmaceutical Corporation 1-800-93NYMOX www.nymox.com For Immediate Release: Nymox Announces $2 Million Private Placement IRVINE, CA (August 2, 2023) Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is pleased to announce an investment of US $2.0 million for 2 million shares at the price of $1.00 per share with
August 2, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August, 2023 Commission File Number: 001-12033 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August, 2023 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation (Translation of registrant’s name into English) Bay & Deveaux Streets, Nassau, The Bahamas (Address of principal exe
July 31, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July, 2023 Commission File Number: 001-12033 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July, 2023 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation (Translation of registrant’s name into English) Bay & Deveaux Streets, Nassau, The Bahamas (Address of principal execu
July 31, 2023	EX-99.1	EX-99.1 EXHIBIT 99.1
July 25, 2023	EX-99.1	EX-99.1 EXHIBIT 99.1
July 25, 2023	EX-99.1	EX-99.1 EXHIBIT 99.1
July 25, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July, 2023 Commission File Number: 001-12033 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July, 2023 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation (Translation of registrant’s name into English) Bay & Deveaux Streets, Nassau, The Bahamas (Address of principal execu
July 25, 2023	EX-99.2	EX-99.2 EXHIBIT 99.2
July 25, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July, 2023 Commission File Number: 001-12033 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July, 2023 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation (Translation of registrant’s name into English) Bay & Deveaux Streets, Nassau, The Bahamas (Address of principal execu
July 12, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2023 Commission File Number: 001-12033 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2023 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation (Translation of registrant’s name into English) Bay & Deveaux Streets, Nassau, The Bahamas (Address of principal execut
July 12, 2023	EX-99.1	NEWS RELEASE EXHIBIT 99.1 NEWS RELEASE For Further Information Contact: Nymox Pharmaceutical Corporation 1-800-93NYMOX www.nymox.com For Immediate Release: Nymox Announces Appointment Of Patrick Doody as Vice President and Member of the Board of Directors of Nymox IRVINE, CA (July 12, 2023) Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is pleased to announce the appointment of Patrick
July 6, 2023	EX-99.1	Nymox Pharmaceutical Corporation EXHIBIT 99.1 NEWS RELEASE For Further Information Contact: Nymox Pharmaceutical Corporation 1-800-93NYMOX www.nymox.com For Immediate Release: Nymox Delisting from NASDAQ IRVINE, CA (July 5, 2023) Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) today received a Nasdaq Hearing Delist Decision, noting that Nymox has not regained the required $1.00 share price within the 6-month exten
July 6, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2023 Commission File Number: 001-12033 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2023 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation (Translation of registrant’s name into English) Bay & Deveaux Streets, Nassau, The Bahamas (Address of principal execut
June 29, 2023	6-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A (Amendment No. 1) REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2023 Commission File UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A (Amendment No. 1) REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2023 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation (Translation of registrant’s name into English) Bay & Deveaux Streets, Nassau, The Bahamas (Address
June 29, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2023 Commission File Number: 001-12033 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2023 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation (Translation of registrant’s name into English) Bay & Deveaux Streets, Nassau, The Bahamas (Address of principal execut
June 27, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2023 Commission File Number: 001-12033 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2023 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation (Translation of registrant’s name into English) Bay & Deveaux Streets, Nassau, The Bahamas (Address of principal execut
May 12, 2023	EX-99.2	CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 99.2 CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended March 31, 2023 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in li
May 12, 2023	6-K	FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended March 31, 2023 Commission File Number: 001-12033 FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended March 31, 2023 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F
May 12, 2023	EX-99.3	CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 99.3 CERTIFICATION I, Christopher Riley, CFO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended March 31, 2023 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the
May 12, 2023	EX-99.1	Payments Due by Period EXHIBIT 99.1 MANAGEMENT’S DISCUSSION AND ANALYSIS (in US dollars) This is Management’s discussion and analysis (“MD&A”) comments on the Corporation’s operations, performance and financial condition as at and for the three months ended March 31, 2023 and 2022. This MD&A should be read together with the unaudited condensed interim Consolidated Financial Statements and the related notes. This MD&A is
May 2, 2023	EX-12.B	CERTIFICATION EXHIBIT 12 (b) CERTIFICATION I, Randall J. Lanham, COO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this annual report for the period ended December 31, 2022 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of t
May 2, 2023	EX-13.A	CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 13 (a) CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, do hereby certify that, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the information contained in the Annual Report for the period e
May 2, 2023	EX-12.A	CERTIFICATION EXHIBIT 12 (a) CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1.
May 2, 2023	20-F	United States Securities and Exchange Commission Washington, D.C. 20549 Form 20-F ☐ Registration Statement pursuant to section 12(b) or (g) of the Securities Exchange Act of 1934 ☒ Annual Report pursuant to section 13 or 15(d) of the Securities Excha United States Securities and Exchange Commission Washington, D.C. 20549 Form 20-F ☐ Registration Statement pursuant to section 12(b) or (g) of the Securities Exchange Act of 1934 or ☒ Annual Report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2022 or ☐ Transition Report pursuant to section 13 or 15(d) of the Securities Exchange Act o
May 2, 2023	EX-13.B	CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 13 (b) CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Randall J. Lanham, COO of Nymox Pharmaceutical Corporation, do hereby certify that, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the information contained in the Annual Report for the period ended Decem
March 31, 2023	NT 20-F	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 000-54332 CUSIP NUMBER (Check one): ☐ Form 10-K ☒ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Re
January 6, 2023	6-K	FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended January 4, 2023 Commission File Number: 001-12033 FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended January 4, 2023 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F
November 16, 2022	EX-99.1	Quarterly Report for the Quarter ended September 30, 2022 EXHIBIT 99.1 MANAGEMENT’S DISCUSSION AND ANALYSIS (in US dollars) This is Management’s discussion and analysis (“MD&A”) comments on the Corporation’s operations, performance and financial condition as of and for the three and nine months ended September 30, 2022 and 2021. This MD&A should be read together with the unaudited interim Consolidated Financial Statements and the related notes. This MD&A
November 16, 2022	6-K/A	Amendment No. 1 FORM 6-K/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended September 30, 2022 Commission File Number: Amendment No. 1 FORM 6-K/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended September 30, 2022 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or
November 16, 2022	EX-99.3	CFO Certifications EX-99.3 4 nymoxex993.htm CFO CERTIFICATION EXHIBIT 99.3 CERTIFICATION I, Randall J, Lanham, COO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended September 30, 2022 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessa
November 16, 2022	6-K/A	Amendment No. 1 FORM 6-K Amendment No. 1 FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended November 10, 2022 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Fo
November 16, 2022	EX-99.2	CEO Certifications EXHIBIT 99.2 CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended September 30, 2022 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, i
November 14, 2022	EX-99.2	CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 99.2 CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended September 30, 2022 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, i
November 14, 2022	EX-99.1	Less than 1 year EXHIBIT 99.1 MANAGEMENT?S DISCUSSION AND ANALYSIS (in US dollars) This is Management?s discussion and analysis (?MD&A?) comments on the Corporation?s operations, performance and financial condition as of and for the three and nine months ended September 30, 2022 and 2021. This MD&A should be read together with the unaudited interim Consolidated Financial Statements and the related notes. This MD&A
November 14, 2022	6-K	FORM 6-K FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended November 10, 2022 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20
November 14, 2022	6-K	FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended September 30, 2022 Commission File Number: 001-12033 FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended September 30, 2022 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 2
November 14, 2022	EX-99.3	CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 99.3 CERTIFICATION I, Randall J, Lanham, COO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended September 30, 2022 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of
August 15, 2022	EX-99.1	Less than 1 year EXHIBIT 99.1 MANAGEMENT'S DISCUSSION AND ANALYSIS (in US dollars) This is Management?s discussion and analysis (?MD&A?) comments on the Corporation?s operations, performance and financial condition as of and for the three and six months ended June 30, 2022 and 2021. This MD&A should be read together with the unaudited condensed interim Consolidated Financial Statements and the related notes. This
August 15, 2022	EX-99.3	CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 99.3 CERTIFICATION I, Randall J, Lanham, COO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended June 30, 2022 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the
August 15, 2022	EX-99.2	CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 99.2 CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended June 30, 2022 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in lig
August 15, 2022	6-K	FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended June 30, 2022 Commission File Number: 001-12033 FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended June 30, 2022 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ?
July 8, 2022	6-K	FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended June 28, 2022 Commission File Number: 001-12033 FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended June 28, 2022 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ?
May 13, 2022	EX-99.1	Payments Due by Period EXHIBIT 99.1 MANAGEMENT?S DISCUSSION AND ANALYSIS (in US dollars) This is Management?s discussion and analysis (?MD&A?) comments on the Corporation?s operations, performance and financial condition as at and for the three months ended March 31, 2022 and 2021. This MD&A should be read together with the unaudited condensed interim Consolidated Financial Statements and the related notes. This MD&A is
May 13, 2022	EX-99.2	CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 99.2 CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended March 31, 2022 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in li
May 13, 2022	EX-99.3	CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 99.3 CERTIFICATION I, Erik Danielsen, CFO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended March 31, 2022 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the ci
May 13, 2022	6-K	FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended March 31, 2022 Commission File Number: 001-12033 FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended March 31, 2022 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F
April 6, 2022	CORRESP	NYMOX PHARMACEUTICAL CORPORATION Bay & Deveaux Streets, Nassau, The Bahamas April 6, 2022 NYMOX PHARMACEUTICAL CORPORATION Bay & Deveaux Streets, Nassau, The Bahamas April 6, 2022 Securities and Exchange Commission Division of Corporation Finance 100 F Street N.
March 30, 2022	EX-13.B	Certification of Chief Financial Officer Pursuant to 18 U.S.C. 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 EXHIBIT 13 (b) CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Erik Danielsen, CFO of Nymox Pharmaceutical Corporation, do hereby certify that, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the information contained in the Annual Report for the period ended December
March 30, 2022	EX-12.A	Certification of Principal Executive Officer Pursuant to Rule 13a-14(a) or 15d-14(a) EXHIBIT 12 (a) CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1.
March 30, 2022	EX-12.B	Certification of Principal Financial Officer Pursuant to Rule 13a-14(a) or 15d-14(a) EXHIBIT 12 (b) CERTIFICATION I, Erik Danielsen, CFO of Nymox Pharmaceutical Corporation, certify that: 1.
March 30, 2022	20-F	United States Securities and Exchange Commission Washington, D.C. 20549 Form 20-F ☐ Registration Statement pursuant to section 12(b) or (g) of the Securities Exchange Act of 1934 ☒ Annual Report pursuant to section 13 or 15(d) of the Securities Excha United States Securities and Exchange Commission Washington, D.C. 20549 Form 20-F ☐ Registration Statement pursuant to section 12(b) or (g) of the Securities Exchange Act of 1934 or ☒ Annual Report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2021 or ☐ Transition Report pursuant to section 13 or 15(d) of the Securities Exchange Act o
March 30, 2022	EX-13.A	Certification of Chief Executive Officer Pursuant to 18 U.S.C. 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 EXHIBIT 13 (a) CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, do hereby certify that, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the information contained in the Annual Report for the period e
March 29, 2022	F-3	As filed with the Securities and Exchange Commission on March 28, 2022 As filed with the Securities and Exchange Commission on March 28, 2022 Registration No.
March 29, 2022	EX-FILING FEES	Filing Fee Table EXHIBIT 107 FILING FEE TABLE CALCULATION OF REGISTRATION FEE Title Of Each Class Of Securities To Be Registered Amount To Be Registered (1)(2) Proposed Maximum Offering Price Per Share (1)(2) Proposed Maximum Aggregate Offering Price Amount Of Registration Fee (2) Common shares stock issuable upon exercise of warrants, No Par Value(1) 3,878,789 $ 1.
March 22, 2022	EX-99.1	NEWS RELEASE EXHIBIT 99.1 NEWS RELEASE For Further Information Contact: Nymox Pharmaceutical Corporation 1-800-93NYMOX www.nymox.com Nymox Announces Closing of $6.4 Million Registered Direct Offering IRVINE, CA (March 22, 2022) Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced the upsizing and closing of its previously announced offering to institutional and accredited investors consisting of 3,8
March 22, 2022	EX-10.2	Placement Agent Agreement EXHIBIT 10.2 March 18, 2022 Nymox Pharmaceutical Corporation Bay & Deveaux Streets Nassau, the Bahamas Attn: Erik Danielsen, Chief Financial Officer Dear Mr. Danielsen: Re: Registered Direct Offering of Common Stock and Concurrent Private Placement of Common Stock Purchase Warrants This letter (the ?Agreement?) constitutes the agreement between A.G.P./Alliance Global Partners (the ?Placement Agent
March 22, 2022	EX-10.1	Form of Securities Purchase Agreement, dated March 18, 2022, between the Company and the investors party thereto EX-10.1 5 nymoxex101.htm EX-10.1 EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 18, 2022, between Nymox Pharmaceutical Corporation, a company incorporated under the International Business Companies Act of the Bahamas (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and
March 22, 2022	424B5	Nymox Pharmaceutical Corporation Filed Pursuant to Rule 424(b)(5) Registration No. 333-261571 PROSPECTUS SUPPLEMENT (to Prospectus dated January 28, 2022) Nymox Pharmaceutical Corporation We are offering 3,878,789 shares of common stock, no par value per share, to several institutional and accredited investors pursuant to this prospectus supplement and the accompanying prospectus and a securities purchase agreement with such inve
March 22, 2022	EX-4.2	Form of Placement Agent Warrant EX-4.2 3 nymoxex42.htm EX-4.2 EXHIBIT 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PU
March 22, 2022	EX-4.1	Form of Investor Warrant EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
March 22, 2022	6-K	FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended March 22, 2022 Commission File Number: 001-12033 FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended March 22, 2022 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F
January 25, 2022	CORRESP	NYMOX PHARMACEUTICAL CORPORATION Bay & Deveaux Streets, Nassau, The Bahamas January 25, 2022 CORRESP 1 filename1.htm NYMOX PHARMACEUTICAL CORPORATION Bay & Deveaux Streets, Nassau, The Bahamas January 25, 2022 Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 Re: Nymox Pharmaceutical Corporation Registration Statement on Form F-3 File No. 333-261571 Acceleration Request Requested Date: January 28, 2022, 11:00 am Eastern Standard Ti
December 9, 2021	EX-10.1	Form of Trust Indenture EXHIBIT 10.1 NYMOX PHARMACEUTICAL CORPORATION and , as Trustee INDENTURE Dated as of , 20 Providing for the Issuance of Debt Securities CROSS-REFERENCE TABLE* Trust Indenture Act Section Indenture Section 310 (a)(1) 6.09 (a)(2) 6.09 (a)(3) N.A. (a)(4) N.A. (a)(5) 6.09 (b) 6.08 311 (a) 6.13 (b) 6.13 312 (a) 7.01; 7.02 (b) 7.02 (c) 7.02 313 (a) 7.03; 1.02 (b) 7.03 (c) 7.03 (d) 7.03 314 (a) 7.04 (b)
December 9, 2021	F-3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-3 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NYMOX PHARMACEUTICAL CORPORATION (Exact name of registrant as specified in its charter) Bahamas Not applicable. (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) Bay & Deveaux Streets Nassau, The Bahamas (Address of
December 9, 2021	EX-10.3	Amendment to Sales Agreement EXHIBIT 10.3 December 3, 2021 Nymox Pharmaceutical Corporation Bay & Deveaux Streets Nassau, The Bahamas Ladies and Gentlemen: Reference is hereby made to that certain sales agreement (the ?Agreement?), dated as of July 17, 2020, by and between Nymox Pharmaceutical Corporation (the ?Company?) and A.G.P./Alliance Global Partners (?A.G.P.?). The Company and A.G.P. hereby agree to amend the Agreement
November 22, 2021	EX-99.1	Notice of annual general meeting on December 14, 2021 EX-99.1 2 nymoxex991.htm EX-99.1 EXHIBIT 99.1 NYMOX PHARMACEUTICAL CORPORATION NOTICE OF THE ANNUAL GENERAL MEETING OF THE SHAREHOLDERS NOTICE IS HEREBY GIVEN that the Annual General Meeting of the shareholders (the “Meeting”) of Nymox Pharmaceutical Corporation (the “Corporation”) will be held at the British Colonial Hilton, Nassau Bahamas, Number One Bay St., Nassau Bahamas, on Tuesday, December
November 22, 2021	EX-99.3	Form of proxy EXHIBIT 99.3
November 22, 2021	EX-99.4	Voting instruction form EX-99.4 5 nymoxex994.htm EX-99.4 EXHIBIT 99.4
November 22, 2021	6-K/A	FORM 6-K/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended November 19, 2021 Commission File Number: 001-12033 FORM 6-K/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended November 19, 2021 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form
November 22, 2021	EX-99.2	Proxy circular EX-99.2 3 nymoxex992.htm EX-99.2 EXHIBIT 99.2 NYMOX PHARMACEUTICAL CORPORATION MANAGEMENT PROXY CIRCULAR November 10, 2021 This proxy circular (the “Circular”) is furnished in connection with the solicitation of proxies by the management of Nymox Pharmaceutical Corporation (the “Corporation”) for use at the Annual General Meeting of the shareholders of the Corporation (the “Meeting”) to be held in
November 19, 2021	EX-99.4	Voting instruction form EX-99.4 5 nymoxex994.htm EX-99.4 EXHIBIT 99.4
November 19, 2021	EX-99.2	NYMOX PHARMACEUTICAL CORPORATION MANAGEMENT PROXY CIRCULAR November 10, 2021 EX-99.2 3 nymoxex992.htm EX-99.2 EXHIBIT 99.2 NYMOX PHARMACEUTICAL CORPORATION MANAGEMENT PROXY CIRCULAR November 10, 2021 This proxy circular (the “Circular”) is furnished in connection with the solicitation of proxies by the management of Nymox Pharmaceutical Corporation (the “Corporation”) for use at the Annual General Meeting of the shareholders of the Corporation (the “Meeting”) to be held in
November 19, 2021	6-K	FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended November 19, 2021 Commission File Number: 001-12033 FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended November 19, 2021 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20
November 19, 2021	EX-99.3	Form of proxy EXHIBIT 99.3
November 19, 2021	EX-99.1	NOTICE OF THE ANNUAL GENERAL MEETING OF THE SHAREHOLDERS EXHIBIT 99.1 NYMOX PHARMACEUTICAL CORPORATION NOTICE OF THE ANNUAL GENERAL MEETING OF THE SHAREHOLDERS NOTICE IS HEREBY GIVEN that the Annual General Meeting of the shareholders (the ?Meeting?) of Nymox Pharmaceutical Corporation (the ?Corporation?) will be held at the British Colonial Hilton, Nassau Bahamas, Number One Bay St., Nassau Bahamas, on Tuesday, December 14, 2021, at 4:30 p.m. (EDT), fo
November 12, 2021	EX-99.2	CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 99.2 CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended September 30, 2021 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, i
November 12, 2021	EX-99.1	Less than 1 year EXHIBIT 99.1 MANAGEMENT?S DISCUSSION AND ANALYSIS (in US dollars) This is Management?s discussion and analysis (?MD&A?) comments on the Corporation?s operations, performance and financial condition as of and for the three and nine months ended September 30, 2021 and 2020. This MD&A should be read together with the unaudited interim Consolidated Financial Statements and the related notes. This MD&A
November 12, 2021	6-K	FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended September 30, 2021 Commission File Number: 001-12033 FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended September 30, 2021 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 2
November 12, 2021	EX-99.3	CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 99.3 CERTIFICATION I, Erik Danielsen, CFO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended September 30, 2021 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of th
August 13, 2021	EX-99.2	CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 99.2 CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended June 30,2021 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in ligh
August 13, 2021	EX-99.1	Less than 1 year EXHIBIT 99.1 MANAGEMENT'S DISCUSSION AND ANALYSIS (in US dollars) This is Management?s discussion and analysis (?MD&A?) comments on the Corporation?s operations, performance and financial condition as of and for the three and six months ended June 30, 2021 and 2020. This MD&A should be read together with the unaudited condensed interim Consolidated Financial Statements and the related notes. This
August 13, 2021	6-K	FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended June 30, 2021 Commission File Number: 001-12033 FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended June 30, 2021 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ☒
August 13, 2021	EX-99.3	CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 99.3 CERTIFICATION I, Erik Danielsen, CFO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended June 30, 2021 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the cir
June 11, 2021	EX-12.B	CERTIFICATION EXHIBIT 12 (b) CERTIFICATION I, Erik Danielsen, CFO of Nymox Pharmaceutical Corporation, certify that: 1.
June 11, 2021	EX-13.B	CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 13 (b) CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Erik Danielsen, CFO of Nymox Pharmaceutical Corporation, do hereby certify that, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the information contained in the Annual Report for the period ended December
June 11, 2021	EX-13.A	CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 13 (a) CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, do hereby certify that, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the information contained in the Annual Report for the period e
June 11, 2021	20-F/A	United States Securities and Exchange Commission Washington, D.C. 20549 Amendment No. 1 Form 20–F ☐ Registration Statement pursuant to section 12(b) or (g) of the Securities Exchange Act of 1934 ☒ Annual Report pursuant to section 13 or 15(d) of the United States Securities and Exchange Commission Washington, D.C. 20549 Amendment No. 1 Form 20?F ? Registration Statement pursuant to section 12(b) or (g) of the Securities Exchange Act of 1934 or ? Annual Report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2020 or ? Transition Report pursuant to section 13 or 15(d) of the Securitie
June 11, 2021	EX-12.A	CERTIFICATION EXHIBIT 12 (a) CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1.
May 17, 2021	CORRESP	NYMOX PHARMACEUTICAL CORPORATION Bay & Deveaux Streets, Nassau, The Bahamas May 14, 2021 NYMOX PHARMACEUTICAL CORPORATION Bay & Deveaux Streets, Nassau, The Bahamas May 14, 2021 Securities and Exchange Commission Division of Corporation Finance 100 F Street N.
May 14, 2021	EX-99.3	CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 99.3 CERTIFICATION I, Erik Danielsen, CFO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended March 31, 2021 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the ci
May 14, 2021	6-K	FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended March 31, 2021 Commission File Number: 001-12033 6-K 1 nymox6k.htm FORM 6-K FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended March 31, 2021 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20
May 14, 2021	EX-99.2	CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 EX-99.2 3 nymoxex992.htm EX-99.2 EXHIBIT 99.2 CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended March 31, 2021 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary t
May 14, 2021	EX-99.1	Payments Due by Period EXHIBIT 99.1 MANAGEMENT?S DISCUSSION AND ANALYSIS (in US dollars) This is Management?s discussion and analysis (?MD&A?) comments on the Corporation?s operations, performance and financial condition as at and for the three months ended March 31, 2021 and 2020. This MD&A should be read together with the unaudited condensed interim Consolidated Financial Statements and the related notes. This MD&A is
May 12, 2021	F-3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-3 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NYMOX PHARMACEUTICAL CORPORATION (Exact name of registrant as specified in its charter) Bahamas Not applicable (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) Bay & Deveaux Streets Nassau, The Bahamas Contact pe
May 6, 2021	EX-10.1	Incorporated by Reference to the Report on 6-K filed May 6, 2021. EXHIBIT 10.1 EXECUTION COPY April 28, 2021 Nymox Pharmaceutical Corporation Bay & Deveaux Streets Nassau, the Bahamas Attn: Erik Danielsen, Chief Financial Officer Dear Mr. Danielsen: Re: Private Placement of Common Stock and Common Stock Purchase Warrants This letter (the ?Agreement?) constitutes the agreement between A.G.P./Alliance Global Partners (the ?Placement Agent?) and Nymox Pharmaceutica
May 6, 2021	6-K	Current Report of Foreign Issuer - FORM 6-K FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended April 30, 2021 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F
May 6, 2021	EX-4.2	Form of Placement Agent Warrant EXHIBIT 4.2 COMMON STOCK PURCHASE WARRANT NYMOX PHARMACEUTICAL CORPORATION Warrant Shares: [ ] Initial Exercise Date: April 30, 2021 Issue Date: April 30, 2021 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, pursuant to a Placement Agent Agreement by and between A.G.P./Alliance Global Partners (?Holder?), as registered owner of this Warrant and Nymox Pharmaceutical Corporation,
May 6, 2021	EX-4.1	Form of Investor Warrant EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
May 6, 2021	EX-99.1	Erik Danielsen EX-99.1 7 nymoxex991.htm EX-99.1 EXHIBIT 99.1 For Further Information Contact: Erik Danielsen Nymox Pharmaceutical Corporation 1-800-93NYMOX www.nymox.com For Immediate Release: NYMOX ANNOUNCES $8,000,000 PRIVATE PLACEMENT HASBROUCK HEIGHTS, NJ (April 28, 2021) Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) today announced it has entered into a definitive agreement with institutio
May 6, 2021	EX-10.3	Registration Rights Agreement dated April 28, 2021 EX-10.3 6 nymoxex103.htm EX-10.3 EXHIBIT 10.3 EXECUTION COPY REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of April 28, 2021, by and between Nymox Pharmaceutical Corporation, a company incorporated under the International Business Companies Act of the Bahamas (the “Company”), and each of the several purchasers signatory hereto (each
May 6, 2021	EX-10.2	Form of Securities Purchase Agreement, dated April 28, 2021, between the Company and the investors party thereto EX-10.2 5 nymoxex102.htm EX-10.2 EXHIBIT 10.2 EXECUTION COPY SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April 28, 2021, between Nymox Pharmaceutical Corporation, a company incorporated under the International Business Companies Act of the Bahamas (the “Company”), and each purchaser identified on the signature pages hereto (each, including its
March 29, 2021	EX-12.B	Certification of Principal Financial Officer Pursuant to Rule 13a-14(a) or 15d-14(a) EXHIBIT 12 (b) CERTIFICATION I, Erik Danielsen, CFO of Nymox Pharmaceutical Corporation, certify that: 1.
March 29, 2021	EX-13.A	Certification of Chief Executive Officer Pursuant to 18 U.S.C. 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 EXHIBIT 13 (a) CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, do hereby certify that, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the information contained in the Annual Report for the period e
March 29, 2021	20-F	- FORM 20-F United States Securities and Exchange Commission Washington, D.C. 20549 Form 20?F ? Registration Statement pursuant to section 12(b) or (g) of the Securities Exchange Act of 1934 or ? Annual Report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2020 or ? Transition Report pursuant to section 13 or 15(d) of the Securities Exchange Act o
March 29, 2021	EX-13.B	Certification of Chief Financial Officer Pursuant to 18 U.S.C. 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 EXHIBIT 13 (b) CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Erik Danielsen, CFO of Nymox Pharmaceutical Corporation, do hereby certify that, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the information contained in the Annual Report for the period ended December
March 29, 2021	EX-12.A	Certification of Principal Executive Officer Pursuant to Rule 13a-14(a) or 15d-14(a) EXHIBIT 12 (a) CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1.
November 20, 2020	EX-99.1	NOTICE OF THE ANNUAL GENERAL MEETING OF THE SHAREHOLDERS EXHIBIT 99.1 NYMOX PHARMACEUTICAL CORPORATION NOTICE OF THE ANNUAL GENERAL MEETING OF THE SHAREHOLDERS NOTICE IS HEREBY GIVEN that the Annual General Meeting of the shareholders (the “Meeting”) of Nymox Pharmaceutical Corporation (the “Corporation”) will be held at the British Colonial Hilton, Nassau Bahamas, Number One Bay St., Nassau Bahamas, on Tuesday, December 21, 2020, at 4:30 p.m. (EDT), fo
November 20, 2020	EX-99.2	NYMOX PHARMACEUTICAL CORPORATION MANAGEMENT PROXY CIRCULAR November 10, 2020 EXHIBIT 99.2 NYMOX PHARMACEUTICAL CORPORATION MANAGEMENT PROXY CIRCULAR November 10, 2020 This proxy circular (the “Circular”) is furnished in connection with the solicitation of proxies by the management of Nymox Pharmaceutical Corporation (the “Corporation”) for use at the Annual General Meeting of the shareholders of the Corporation (the “Meeting”) to be held in Nassau Bahamas on December 21, 2
November 20, 2020	6-K	Current Report of Foreign Issuer - FORM 6-K FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended November 19, 2020 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20
November 20, 2020	EX-99.3	Form of proxy EXHIBIT 99.3
November 19, 2020	6-K	Current Report of Foreign Issuer - FORM 6-K FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended November 18, 2020 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20
November 13, 2020	EX-99.2	CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 99.2 CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended September 30, 2020 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, i
November 13, 2020	EX-99.3	CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 99.3 CERTIFICATION I, Erik Danielsen, CFO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended September 30, 2020 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of th
November 13, 2020	6-K	Current Report of Foreign Issuer - FORM 6-K FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended September 30, 2020 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 2
November 13, 2020	EX-99.1	Less than 1 year EXHIBIT 99.1 MANAGEMENT’S DISCUSSION AND ANALYSIS (in US dollars) This is Management’s discussion and analysis (“MD&A”) comments on the Corporation’s operations, performance and financial condition as of and for the three and nine months ended September 30, 2020 and 2019. This MD&A should be read together with the unaudited interim Consolidated Financial Statements and the related notes. This MD&A
October 13, 2020	EX-16.1	Letter from Thayer O’Neal Company, LLC dated October 13, 2020 regarding change in certifying accountant EXHIBIT 16.1 United States Securities and Exchange Commission Office of the Chief Accountant 100 F Street, N.E. Washington, D.C. 20549 Ladies and Gentlemen: We have read the statements under Item 4.01 in the Form 6-K dated October 13, 2020, of Nymox Pharmaceutical Corp. (the “Company”) to be filed with the Securities and Exchange Commission and we agree with such statements therein as related to o
October 13, 2020	6-K	Current Report of Foreign Issuer - FORM 6-K FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended October 13, 2020 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-
August 14, 2020	424B5	$9,000,000 Nymox Pharmaceutical Corporation Filed Pursuant to Rule 424(b)(5) Registration No. 333-237564 PROSPECTUS SUPPLEMENT (to Prospectus dated May 13, 2020) $9,000,000 Nymox Pharmaceutical Corporation We are offering 3,600,000 shares of our common stock pursuant to this prospectus supplement and the accompanying prospectus at an offering price of $2.50 per share. Our shares of common stock are traded on the Nasdaq Capital Market under
August 14, 2020	EX-99.1	Erik Danielsen EXHIBIT 99.1 For Further Information Contact: Erik Danielsen Nymox Pharmaceutical Corporation 1-800-93NYMOX www.nymox.com For Immediate Release: Nymox Announces Closing of $9 Million Registered Direct Offering HASBROUCK HEIGHTS, NJ (August 14, 2020) Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced the closing of a registered direct offering of 3,600,000 shares of its common stock, a
August 14, 2020	6-K	Current Report of Foreign Issuer - FORM 6-K FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended June 30, 2020 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ☒
August 14, 2020	6-K	Current Report of Foreign Issuer - FORM 6-K FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended August 14, 2020 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F
August 14, 2020	EX-99.1	Less than 1 year EXHIBIT 99.1 MANAGEMENT'S DISCUSSION AND ANALYSIS (in US dollars) This is Management’s discussion and analysis (“MD&A”) comments on the Corporation’s operations, performance and financial condition as of and for the three and six months ended June 30, 2020 and 2019. This MD&A should be read together with the unaudited condensed interim Consolidated Financial Statements and the related notes. This
August 14, 2020	EX-99.3	CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 99.3 CERTIFICATION I, Erik Danielsen, CFO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended June 30, 2020 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the cir
August 14, 2020	424B5	Nymox Pharmaceutical Corporation Up to $2,872,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-237564 AMENDMENT NO. 1 DATED AUGUST 12, 2020 to PROSPECTUS SUPPLEMENT DATED JULY 17, 2020 (to Prospectus dated May 13, 2020) Nymox Pharmaceutical Corporation Up to $2,872,000 Shares of Common Stock This Amendment No. 1 to Prospectus Supplement (this “Amendment”) amends and supplements the information in our prospectus supplement dated July 17,
August 14, 2020	EX-99.2	CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 99.2 CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended June 30,2020 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in ligh
August 14, 2020	EX-10.2	Securities Purchase Agreement, dated August 12, 2020, between the Company and the investors party thereto EXHIBIT 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of August 12, 2020, between Nymox Pharmaceutical Corporation, a company incorporated under the International Business Companies Act of the Bahamas (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and coll
August 14, 2020	EX-10.1	Placement Agent Agreement, dated August 12, 2020, between the Company and the Placement Agent EXHIBIT 10.1 August 12, 2020 Nymox Pharmaceutical Corporation Bay & Deveaux Streets Nassau, the Bahamas Attn: Erik Danielsen, Chief Financial Officer Dear Mr. Danielsen: This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners (the “Placement Agent”) and Nymox Pharmaceutical Corporation, a company incorporated under the International Business Companies Act of
August 13, 2020	6-K	Current Report of Foreign Issuer - FORM 6-K FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended August 11, 2020 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F
August 13, 2020	EX-99.1	July 30, 2020 EXHIBIT 99.1 July 30, 2020 Nymox Pharmaceutical Corporation Bay & Deveaux Streets Nassau, The Bahamas Re: Nymox Pharmaceutical Corporation Registration Statement on Form F-3 Ladies and Gentlemen: We have acted as special counsel to Nymox Pharmaceutical Corporation, a Bahamian corporation (the “Company”), in connection with the preparation and filing with the Securities and Exchange Commission (the
August 12, 2020	EX-99.1	Erik Danielsen EXHIBIT 99.1 For Further Information Contact: Erik Danielsen Nymox Pharmaceutical Corporation 1-800-93NYMOX www.nymox.com For Immediate Release: Nymox Announces $9 Million Registered Direct Offering HASBROUCK HEIGHTS, NJ (August 12, 2020) Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced it has entered into definitive agreements with institutional and accredited investors for the pur
August 12, 2020	6-K	Current Report of Foreign Issuer - FORM 6-K FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended August 12, 2020 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F
July 20, 2020	6-K	Current Report of Foreign Issuer - FORM 6-K FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended July 17, 2020 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ☒
July 20, 2020	EX-99.1	NYMOX PHARMACEUTICAL CORPORATION COMMON STOCK SALES AGREEMENT EXHIBIT 99.1 NYMOX PHARMACEUTICAL CORPORATION COMMON STOCK SALES AGREEMENT July 17, 2020 A.G.P./Alliance Global Partners 590 Madison Avenue New York, NY 10022 Ladies and Gentlemen: Nymox Pharmaceutical Corporation, a company incorporated under the International Business Companies Act of the Bahamas (the “Company”), confirms its agreement (this “Agreement”) with A.G.P./Alliance Global Partners, as
July 17, 2020	424B5	Nymox Pharmaceutical Corporation Up to $12,000,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-237564 PROSPECTUS SUPPLEMENT (to Prospectus dated May 13, 2020) Nymox Pharmaceutical Corporation Up to $12,000,000 Shares of Common Stock This prospectus supplement and accompanying prospectus relates to the issuance and sale of up to $12,000,000 of our common stock, no par value per share, from time to time through our sales agent, A.G.P. / Al
May 14, 2020	EX-99.3	CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 99.3 CERTIFICATION I, Erik Danielsen, CFO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended March 31, 2020 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the ci
May 14, 2020	6-K	Current Report of Foreign Issuer - FORM 6-K FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended March 31, 2020 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F
May 14, 2020	EX-99.2	CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 99.2 CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended March 31, 2020 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in li
May 14, 2020	EX-99.1	Payments Due by Period EXHIBIT 99.1 MANAGEMENT’S DISCUSSION AND ANALYSIS (in US dollars) This is Management’s discussion and analysis (“MD&A”) comments on the Corporation’s operations, performance and financial condition as at and for the three months ended March 31, 2020 and 2019. This MD&A should be read together with the unaudited condensed interim Consolidated Financial Statements and the related notes. This MD&A is
May 7, 2020	CORRESP	- NYMOX PHARMACEUTICAL CORPORATION Bay & Deveaux Streets, Nassau, The Bahamas May 7, 2020 Securities and Exchange Commission Division of Corporation Finance 100 F Street N.
May 6, 2020	F-3/A	- F-3/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NYMOX PHARMACEUTICAL CORPORATION (Exact name of registrant as specified in its charter) Bahamas The NASDAQ Stock Market, LLC (NASDAQ Capital Market) (State or other jurisdiction of incorporation or organization) (Name of each exchange on which eac
April 24, 2020	F-3/A	- FORM F-3/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NYMOX PHARMACEUTICAL CORPORATION (Exact name of registrant as specified in its charter) Bahamas The NASDAQ Stock Market, LLC (NASDAQ Capital Market) (State or other jurisdiction of incorporation or organization) (Name of each exchange on which eac
April 24, 2020	6-K	Current Report of Foreign Issuer - FORM 6-K FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended April 23, 2020 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F x Form 40-F o Indicate by check ma
April 24, 2020	EX-10	Form of Trust Indenture EXHIBIT 10 NYMOX PHARMACEUTICAL CORPORATION and , as Trustee INDENTURE Dated as of , 20 Providing for the Issuance of Debt Securities CROSS-REFERENCE TABLE* Trust Indenture Act Section Indenture Section 310 (a)(1) 6.
April 3, 2020	F-3	NYMX / Nymox Pharmaceutical Corp. F-3 - - FORM F-3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NYMOX PHARMACEUTICAL CORPORATION (Exact name of registrant as specified in its charter) Bahamas The NASDAQ Stock Market, LLC (NASDAQ Capital Market) (State or other jurisdiction of incorporation or organization) (Name of each exchange on which each stock it to be
March 30, 2020	EX-12.B	Certification of Principal Financial Officer Pursuant to Rule 13a-14(a) or 15d-14(a) EXHIBIT 12 (b) CERTIFICATION I, Erik Danielsen, CFO of Nymox Pharmaceutical Corporation, certify that: 1.
March 30, 2020	EX-13.B	Certification of Chief Financial Officer Pursuant to 18 U.S.C. 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 EXHIBIT 13 (b) CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Erik Danielsen, CFO of Nymox Pharmaceutical Corporation, do hereby certify that, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the information contained in the Annual Report for the period ended December
March 30, 2020	20-F	NYMX / Nymox Pharmaceutical Corp. 20-F - - FORM 20-F United States Securities and Exchange Commission Washington, D.C. 20549 Form 20–F ¨ Registration Statement pursuant to section 12(b) or (g) of the Securities Exchange Act of 1934 or ☒ Annual Report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2019 or ☐ Transition Report pursuant to section 13 or 15(d) of the Securities Exchange Act o
March 30, 2020	EX-13.A	Certification of Chief Executive Officer Pursuant to 18 U.S.C. 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 EXHIBIT 13 (a) CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, do hereby certify that, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the information contained in the Annual Report for the period e
March 30, 2020	EX-12.A	Certification of Principal Executive Officer Pursuant to Rule 13a-14(a) or 15d-14(a) EXHIBIT 12 (a) CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1.
November 19, 2019	6-K	NYMX / Nymox Pharmaceutical Corp. 6-K - Current Report of Foreign Issuer - REPORT OF FOREIGN ISSUER FOR THE PERIOD ENDED NOVEMBER 19, 2019 Filed by e3 Filing, Computershare 1-800-973-3274 - Nymox Pharmaceutical Corporation - Form 6-K FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.
November 19, 2019	EX-99.3	Proxies submitted must be received by 5:00 pm, Eastern Time, on December 14, 2019. Exhibit 99.3 Exhibit 99.3 8th Floor, 100 University Avenue Toronto, Ontario M5J 2Y1 www.computershare.com Security Class Holder Account Number Form of Proxy - Annual General Meeting to be held on December 17, 2019 This Form of Proxy is solicited by and on behalf of Management. Notes to proxy 1. Every holder has the right to appoint some other person or company of their choice, who need not be a ho
November 19, 2019	EX-99.1	NYMOX PHARMACEUTICAL CORPORATION Exhibit 99.1 Exhibit 99.1 NYMOX PHARMACEUTICAL CORPORATION NOTICE OF THE ANNUAL GENERAL MEETING OF THE SHAREHOLDERS NOTICE IS HEREBY GIVEN that the Annual General Meeting of the shareholders (the “Meeting”) of Nymox Pharmaceutical Corporation (the “Corporation”) will be held at the British Colonial Hilton, Nassau Bahamas, Number One Bay St., Nassau Bahamas, on Tuesday, December 17, 2019, at 4:30 p
November 19, 2019	EX-99.2	NYMOX PHARMACEUTICAL CORPORATION MANAGEMENT PROXY CIRCULAR November 15, 2019 Exhibit 99.2 Exhibit 99.2 NYMOX PHARMACEUTICAL CORPORATION MANAGEMENT PROXY CIRCULAR November 15, 2019 This proxy circular (the “Circular ”) is furnished in connection with the solicitation of proxies by the management of Nymox Pharmaceutical Corporation (the “Corporation”) for use at the Annual General Meeting of the shareholders of the Corporation (the “Meeting”) to be held in Nassau Bahamas on
November 13, 2019	EX-99.2	CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 99.3 CERTIFICATION I, Erik Danielsen, CFO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended September 30, 2019 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of th
November 13, 2019	EX-99.1	Less than 1 year EXHIBIT 99.1 MANAGEMENT’S DISCUSSION AND ANALYSIS (in US dollars) This is Management’s discussion and analysis (“MD&A”) comments on the Corporation’s operations, performance and financial condition as of and for the three and nine months ended September 30, 2019 and 2018. This MD&A should be read together with the unaudited interim Consolidated Financial Statements and the related notes. This MD&A
November 13, 2019	6-K	NYMX / Nymox Pharmaceutical Corp. 6-K - Current Report of Foreign Issuer - FORM 6-K FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended September 30, 2019 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 2
November 13, 2019	EX-99.2	CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 99.2 CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended September 30, 2019 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, i
August 14, 2019	EX-99.1	Less than 1 year EXHIBIT 99.1 MANAGEMENT'S DISCUSSION AND ANALYSIS (in US dollars) This is Management’s discussion and analysis (“MD&A”) comments on the Corporation’s operations, performance and financial condition as of and for the three and six months ended June 30, 2019 and 2018. This MD&A should be read together with the unaudited condensed interim Consolidated Financial Statements and the related notes. This
August 14, 2019	EX-99.3	CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 99.3 CERTIFICATION I, Erik Danielsen, CFO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended June 30, 2019 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the cir
August 14, 2019	EX-99.2	CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 99.2 CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended June 30,2019 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in ligh
August 14, 2019	6-K	NYMX / Nymox Pharmaceutical Corp. 6-K - Current Report of Foreign Issuer - FORM 6-K FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended June 30, 2019 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F x
May 15, 2019	EX-99.1	Less than 1 year EXHIBIT 99.1 MANAGEMENT’S DISCUSSION AND ANALYSIS (in US dollars) This is Management’s discussion and analysis (“MD&A”) comments on the Corporation’s operations, performance and financial condition as at and for the three months ended March 31, 2019 and 2018. This MD&A should be read together with the unaudited condensed interim Consolidated Financial Statements and the related notes. This MD&A is
May 15, 2019	EX-99.3	CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 99.3 CERTIFICATION I, Erik Danielsen, CFO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended March 31, 2019 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the ci
May 15, 2019	6-K	NYMX / Nymox Pharmaceutical Corp. 6-K Current Report of Foreign Issuer FORM 6-K FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended March 31, 2019 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F
May 15, 2019	EX-99.2	CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 99.2 CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended March 31, 2019 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in li
March 29, 2019	20-F	NYMX / Nymox Pharmaceutical Corp. FORM 20-F United States Securities and Exchange Commission Washington, D.C. 20549 Form 20–F ¨ Registration Statement pursuant to section 12(b) or (g) of the Securities Exchange Act of 1934 or x Annual Report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2018 or o Transition Report pursuant to section 13 or 15(d) of the Securities Exchange Act o
March 29, 2019	EX-12.A	Certification of Principal Executive Officer Pursuant to Rule 13a-14(a) or 15d-14(a) EXHIBIT 12 (a) CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1.
March 29, 2019	EX-12.B	Certification of Principal Financial Officer Pursuant to Rule 13a-14(a) or 15d-14(a) EXHIBIT 12 (b) CERTIFICATION I, Erik Danielsen, CFO of Nymox Pharmaceutical Corporation, certify that: 1.
March 29, 2019	EX-13.A	Certification of Chief Executive Officer Pursuant to 18 U.S.C. 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 EXHIBIT 13 (a) CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, do hereby certify that, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the information contained in the Annual Report for the period e
March 29, 2019	EX-13.B	Certification of Chief Financial Officer Pursuant to 18 U.S.C. 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 EXHIBIT 13 (b) CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Erik Danielsen, CFO of Nymox Pharmaceutical Corporation, do hereby certify that, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the information contained in the Annual Report for the period ended December
November 24, 2018	EX-99.3	Proxies submitted must be received by 5:00 pm, Eastern Time, on December 14, 2018. Exhibit 99.3 Exhibit 99.3 8th Floor, 100 University Avenue Toronto, Ontario M5J 2Y1 www.computershare.com Security Class Holder Account Number Form of Proxy - Annual General Meeting to be held on December 18, 2018 This Form of Proxy is solicited by and on behalf of Management. Notes to proxy 1. Every holder has the right to appoint some other person or company of their choice, who need not be a ho
November 24, 2018	EX-99.2	NYMOX PHARMACEUTICAL CORPORATION NOTICE OF THE ANNUAL GENERAL MEETING OF THE SHAREHOLDERS Exhibit 99.2 Exhibit 99.2 NYMOX PHARMACEUTICAL CORPORATION NOTICE OF THE ANNUAL GENERAL MEETING OF THE SHAREHOLDERS NOTICE IS HEREBY GIVEN that the Annual General Meeting of the shareholders (the “Meeting”) of Nymox Pharmaceutical Corporation (the “Corporation”) will be held at the British Colonial Hilton, Nassau Bahamas, Number One Bay St., Nassau Bahamas, on Tuesday, December 18, 2018, at 4:30 p
November 24, 2018	EX-99.1	NYMOX PHARMACEUTICAL CORPORATION NOTICE OF THE ANNUAL GENERAL MEETING OF THE SHAREHOLDERS Exhibit 99.1 Exhibit 99.1 NYMOX PHARMACEUTICAL CORPORATION NOTICE OF THE ANNUAL GENERAL MEETING OF THE SHAREHOLDERS NOTICE IS HEREBY GIVEN that the Annual General Meeting of the shareholders (the “Meeting”) of Nymox Pharmaceutical Corporation (the “Corporation”) will be held at the British Colonial Hilton, Nassau Bahamas, Number One Bay St., Nassau Bahamas, on Tuesday, December 18, 2018, at 4:30 p
November 24, 2018	6-K	NYMX / Nymox Pharmaceutical Corp. REPORT OF FOREIGN ISSUER FOR NOVEMBER 2018 (Current Report of Foreign Issuer) Filed by e3 Filing, Computershare 1-800-973-3274 - Nymox Pharmaceutical Corporation - Form 6-K FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.
November 13, 2018	EX-99.3	CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 99.3 CERTIFICATION I, Erik Danielsen, CFO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended September 30, 2018 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of th
November 13, 2018	EX-99.2	CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 99.2 CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended September 30, 2018 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, i
November 13, 2018	6-K	NYMX / Nymox Pharmaceutical Corp. FORM 6-K (Current Report of Foreign Issuer) FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended September 30, 2018 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 2
November 13, 2018	EX-99.1	Less than 1 year EXHIBIT 99.1 MANAGEMENT’S DISCUSSION AND ANALYSIS (in US dollars) This is Management’s discussion and analysis (“MD&A”) comments on the Corporation’s operations, performance and financial condition as of and for the three and nine months ended September 30, 2018 and 2017. This MD&A should be read together with the unaudited interim Consolidated Financial Statements and the related notes. This MD&A
August 13, 2018	EX-99.2	CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 99.2 CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended June 30 2018 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in ligh
August 13, 2018	EX-99.3	18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 99.3 CERTIFICATION I, Erik Danielsen, CFO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended June 30, 2018 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the cir
August 13, 2018	6-K	NYMX / Nymox Pharmaceutical Corp. FORM 6-K (Current Report of Foreign Issuer) FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended June 30, 2018 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F x
August 13, 2018	EX-99.1	Less than 1 year EXHIBIT 99.1 MANAGEMENT'S DISCUSSION AND ANALYSIS (in US dollars) This is Management’s discussion and analysis (“MD&A”) comments on the Corporation’s operations, performance and financial condition as of and for the three and six months ended June 30, 2018 and 2017. This MD&A should be read together with the unaudited condensed interim Consolidated Financial Statements and the related notes. This
May 15, 2018	EX-99.1	Less than 1 year EXHIBIT 99.1 MANAGEMENT'S DISCUSSION AND ANALYSIS (in US dollars) This Management’s discussion and analysis (“MD&A”) comments on the Corporation’s operations, performance and financial condition as at and for the three months ended March 31, 2018 and 2017. This MD&A should be read together with the unaudited condensed interim Consolidated Financial Statements and the related notes. This MD&A is da
May 15, 2018	EX-99.3	CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 CERTIFICATION I, Erik Danielsen, CFO of Nymox Pharmaceutical Corporation, certify that: 1.
May 15, 2018	EX-99.2	CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 EX-99.2 3 nymxex992.htm CEO CERTIFICATION CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended March 31, 2018 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to ma
May 15, 2018	6-K	NYMX / Nymox Pharmaceutical Corp. FORM 6-K (Current Report of Foreign Issuer) FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended March 31, 2018 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F
May 11, 2018	EX-13.A	Certification of Chief Executive Officer Pursuant to 18 U.S.C. 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 EXHIBIT 13 (a) CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, do hereby certify that, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the information contained in the Annual Report for the period e
May 11, 2018	EX-12.A	Certification of Principal Financial Officer Pursuant to Rule 13a-14(a) or 15d-14(a) EXHIBIT 12 (a) CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1.
May 11, 2018	20-F/A	NYMX / Nymox Pharmaceutical Corp. FORM 20-F AMENDMENT NO. 1 United States Securities and Exchange Commission Washington, D.C. 20549 Form 20–F/A Amendment No. 1 ¨ Registration Statement pursuant to section 12(b) or (g) of the Securities Exchange Act of 1934 or x Annual Report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2017 or o Transition Report pursuant to section 13 or 15(d) of the Securit
May 11, 2018	EX-13.B	Certification of Chief Financial Officer Pursuant to 18 U.S.C. 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 EXHIBIT 13 (b) CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Erik Danielsen, CFO of Nymox Pharmaceutical Corporation, do hereby certify that, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the information contained in the Annual Report for the period ended December
May 11, 2018	EX-12.B	Certification of Principal Executive Officer Pursuant to Rule 13a-14(a) or 15d-14(a) EXHIBIT 12 (b) CERTIFICATION I, Erik Danielsen, CFO of Nymox Pharmaceutical Corporation, certify that: 1.
April 26, 2018	6-K	NYMX / Nymox Pharmaceutical Corp. FORM 6-K (Current Report of Foreign Issuer) FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of April 2018 Nymox Pharmaceutical Corporation 1 St. Bay & Deveaux Streets Nassau, The Bahamas (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports un
March 30, 2018	20-F	NYMX / Nymox Pharmaceutical Corp. FORM 20-F United States Securities and Exchange Commission Washington, D.C. 20549 Form 20–F ¨ Registration Statement pursuant to section 12(b) or (g) of the Securities Exchange Act of 1934 or x Annual Report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2017 or o Transition Report pursuant to section 13 or 15(d) of the Securities Exchange Act o
March 30, 2018	EX-12.B	Certification of Principal Executive Officer Pursuant to Rule 13a-14(a) or 15d-14(a) EXHIBIT 12 (b) CERTIFICATION I, Erik Danielsen, CFO of Nymox Pharmaceutical Corporation, certify that: 1.
March 30, 2018	EX-12.A	Certification of Principal Financial Officer Pursuant to Rule 13a-14(a) or 15d-14(a) EXHIBIT 12 (a) CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1.
March 30, 2018	EX-13.A	Certification of Chief Executive Officer Pursuant to 18 U.S.C. 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 EXHIBIT 13 (a) CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, do hereby certify that, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the information contained in the Annual Report for the period e
March 30, 2018	EX-13.B	Certification of Chief Financial Officer Pursuant to 18 U.S.C. 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 EXHIBIT 13 (b) CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Erik Danielsen, CFO of Nymox Pharmaceutical Corporation, do hereby certify that, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the information contained in the Annual Report for the period ended December
December 2, 2017	EX-99.2	Form of Proxy nymoxex992.htm EXHIBIT 99.2
December 2, 2017	6-K	NYMX / Nymox Pharmaceutical Corp. FORM 6-K (Current Report of Foreign Issuer) nymox6k.htm FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For December 1, 2017 Nymox Pharmaceutical Corporation 1 St. Bay & Deveaux Streets Nassau, The Bahamas (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual repor
December 2, 2017	EX-99.1	NYMOX PHARMACEUTICAL CORPORATION NOTICE OF THE ANNUAL GENERAL MEETING OF THE SHAREHOLDERS nymoxex991.htm EXHIBIT 99.1 NYMOX PHARMACEUTICAL CORPORATION NOTICE OF THE ANNUAL GENERAL MEETING OF THE SHAREHOLDERS NOTICE IS HEREBY GIVEN that the Annual General Meeting of the shareholders (the ?Meeting?) of Nymox Pharmaceutical Corporation (the ?Corporation?) will be held at the British Colonial Hilton, Nassau Bahamas, Number One Bay St., Nassau Bahamas, on Tuesday, December 19, 2017, at 4:30
November 6, 2017	6-K	NYMX / Nymox Pharmaceutical Corp. FORM 6-K (Current Report of Foreign Issuer) nymox6k.htm FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended September 30, 2017 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form
November 6, 2017	EX-99.2	CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 nymoxex992.htm EXHIBIT 99.2 CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended September 30, 2017 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the sta
November 6, 2017	EX-99.3	CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 nymoxex993.htm EXHIBIT 99.3 CERTIFICATION I, Erik Danielsen, CFO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended September 30, 2017 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,

NYMX / Nymox Pharmaceutical Corp - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)